KRAS Inhibitors Market on Track for Major Expansion by 2034, According to DelveInsight | Pfizer, Roche, Chugai, Genentech, Revolution Medicines, Eli Lilly, Merck, Taiho, Astex Pharma, Elicio Therapeut

The Key KRAS Inhibitors Companies in the market include - Pfizer, Roche/Chugai/Genentech, Revolution Medicines, Eli Lilly and Company, Merck, Taiho, and Astex Pharmaceuticals, Elicio Therapeutics, Jiangsu Hengrui Pharmaceuticals, Cardiff Oncology, Genfleet Therapeutics and Innovent, Jacobio Pharma, Tyligand Pharmaceuticals (Suzhou), Silexion Therapeutics and Catalent, Astellas Pharma, Incyte, Quanta Therapeutics, and others.

DelveInsight's "KRAS Inhibitors Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the KRAS Inhibitors, historical and forecasted epidemiology as well as the KRAS Inhibitors market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the KRAS Inhibitors market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; KRAS Inhibitors Market Forecast [https://www.delveinsight.com/sample-request/kras-inhibitors-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the KRAS Inhibitors Market Report:

*
The KRAS inhibitors market size across the 7MM was estimated at USD 526 million in 2025 and is anticipated to grow significantly with a CAGR of 35%, reaching USD 7,847 million by 2034 over the forecast period from 2025 to 2034.

*
In May 2025, Verastem Oncology announced that the U.S. FDA has granted approval for AVMAPKI + FAKZYNJA CO-PACK (avutometinib capsules and defactinib tablets) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have previously received systemic therapy. This combination marks the first and only FDA-approved treatment for this condition. The approval was granted under the accelerated approval pathway, based on tumor response rate and duration of response (DoR).

*
In April 2025, BMS announced anticipation of Phase III trial data readouts for KRYSTAL-10 by 2026 for 2L CRC, KRYSTAL-7 trial results in 2028 for 1L NSCLC PD-L1=50%, and KRYSTAL-4 trial results in 2029 for 1L.

*
In March 2025, Verastem Oncology announced plans to launch avutometinib in the first-half of 2025 to maximize market opportunity in KRAS mutant recurrent LGSOC. The company plans to submit for National Comprehensive Cancer Network (NCCN) Guideline inclusion upon FDA approval, which may enable patients with KRAS wild-type LGSOC to access therapy.

*
According to BMS's Q1 2025 presentations, KRAZATI (KRYSTAL-17) early-stage data for 1L NSCLC (TPS



This release was published on openPR.